Potential first-in-class

Discover the landscape of Potential first-in-class in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Potential first-in-class, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

FDA Approves Viatris's RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label
CompanyDrug

FDA Approves Viatris’s RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label

Viatris Inc. (NASDAQ: VTRS) announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is already…

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Zelgen Biopharmaceuticals’ ZG006 Earns NMPA Approval for Clinical Trials in Solid Tumors

CompanyDrug

Huadong Medicine Receives NMPA Approval for Phase I Clinical Trial of DR10624 for Weight Management

CompanyDrug

Gilead Sciences Halts Development of Magrolimab for HR-MDS Following Phase III Trial Results

CompanyDeals

Coherent Biopharma and C-Ray Therapeutics Partner to Advance Peptide-Drug Conjugate Development

CompanyDrug

Nanjing Leads Biolabs Receives FDA IND Approval for LBL-033 Phase I/II Clinical Trial

CompanyDrug

Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study

CompanyDeals

AstraZeneca Enters Three-Year Collaboration with Cholesgen for Metabolic Disease Therapies

CompanyLegal / IP

AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa

Show More